CVS Q1 Earnings Beat, Raises 2026 Guidance

CVS Health reported Q1 earnings that exceeded forecasts and raised its 2026 guidance after a significant margin recovery in its Health Care Benefits segment, the company said on May 6, 2026. Management cited this improvement as the basis for the outlook while noting ongoing elevated cost risks.

Earnings Beat and Raised Guidance

The SEC 8-K filed premarket showed first-quarter total revenue of $100.4 billion, up 6.2% year over year from $94.6 billion. GAAP diluted earnings per share (EPS) were $2.30, and adjusted EPS was $2.57, surpassing the consensus estimate of $2.21. CVS raised its full-year 2026 guidance for GAAP diluted EPS to a range of $6.24 to $6.44, adjusted EPS to $7.30 to $7.50, and cash flow from operations to at least $9.5 billion. The company attributed the increase to gains in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining caution due to elevated cost trends and potential macroeconomic headwinds.

Health Care Benefits Segment Drives Gains

The Health Care Benefits unit generated $36.0 billion in revenue and $3.0 billion in adjusted operating income, a 52.6% increase from about $2.0 billion a year earlier. The medical benefit ratio (MBR), which measures claims paid as a percentage of premiums, improved to 84.6% from 87.3%. The gain reflected stronger underlying performance in the Government business and the absence of a $448 million premium-deficiency reserve recorded in the prior year. The company also cited a favorable Medicare Advantage final rate notice and a home-health assessment policy from the Centers for Medicare & Medicaid Services, which provide clearer visibility into 2027.

Company-wide adjusted operating income rose 12.5% year over year, and operating income increased 38.7%, helped by the absence of prior-year charges including a $387 million litigation expense and a $247 million divestiture loss. Net income for the quarter was $2.9 billion.

Offsets to the insurer’s strength included weaker results in other segments. Health Services revenue was $48.2 billion, but its adjusted operating income fell 7.1% year over year. Pharmacy & Consumer Wellness adjusted operating income declined 8.8%. Medical membership stood at about 26.0 million, down roughly 1.1 million year over year. Days claims payable rose to 42.9 days, up 4.0 days from the prior year. The Pharmacy & Consumer Wellness segment filled approximately 451 million 30-day equivalent prescriptions.

"The Company is increasing its full-year 2026 GAAP diluted EPS, Adjusted EPS and cash flow from operations guidance to reflect increases in the Health Care Benefits and Pharmacy & Consumer Wellness segments, while maintaining a cautious view for the remainder of the year in light of continued elevated cost trends and the potential for macro headwinds," the company said in its May 6 press release.